Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $224.30M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.45M
Average 0.49M
BCYC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Bicycle Therapeutics plcNASDAQ: BCYC
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$59.48M, compared with -$60.25M a year earlier. Trailing-twelve-month EBITDA was -$211.5M.
Context
- EBITDA amounted to 292.3% of revenue in FY2025, down 175.1 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$148.78M (+29.9%) for the fiscal year ending Dec 2026, a step up from the -28.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$59.48M-239.9% QoQ
- Last fiscal yearDec 2025
- -$212.18M-28.7% YoY
- LTMMar 2026
- -$211.5M-0.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.3% | +49.4% | +48.1 pp |
| 1 year | -28.7% | +29.9% | +58.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (212.18M) USD
- Year-over-year change
- -28.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (212.18M) | -28.7% |
| FY2024 | 2024-12-31 | (164.89M) | +2.7% |
| FY2023 | 2023-12-31 | (169.4M) | -58.0% |
| FY2022 | 2022-12-31 | (107.21M) | -67.3% |
| FY2021 | 2021-12-31 | (64.09M) | — |
EBITDA vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's LTM Mar 2026 EBITDA of -$211.5M is the 9th highest of the 10 companies compared; the peer median is -$74.74M.
- Its year-over-year change of -0.8% is the 7th highest of 9, against a peer median of +14.5%.
- EBITDA amounts to 333.1% of revenue for BCYC, versus a peer median of 117.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $92.9M | +159.9% | — | 939.0% | |
| LTM Mar 2026 | -$17.44M | +88.7% | — | 25.0% | |
| LTM Mar 2026 | -$67.05M | -25.2% | — | — | |
| LTM Mar 2026 | -$74.72M | +35.0% | — | 129.0% | |
| LTM Mar 2026 | -$74.74M | -18129.5% | — | — | |
| LTM Mar 2026 | -$83.2M | +13.7% | — | 105.1% | |
| LTM Dec 2025 | -$117.15M | — | — | 101.1% | |
| LTM Mar 2026 | -$163.43M | +3.9% | — | 185.2% | |
| LTM Mar 2026 | -$211.5M | -0.8% | — | 333.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M | +15.4% | — | — |
| Peer median (excluding BCYC) | -$74.74M | +14.5% | — | 117.0% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.7M | 14.46M | 26.98M | 35.28M | 72.59M |
| Cost of Revenue | 0 | 0 | 156.5M | 172.97M | 0 |
| Gross Profit | 11.7M | 14.46M | (129.52M) | (137.69M) | 72.59M |
| Gross Margin | 100.0% | 100.0% | -480.1% | -390.3% | 100.0% |
| Research & Development | 44.88M | 81.61M | 156.5M | 172.97M | 240.28M |
| Selling, General & Admin | 32.44M | 49.51M | 59.83M | 71.46M | 80.02M |
| Operating Expenses | 77.32M | 131.12M | 60.43M | 72.18M | 320.3M |
| Depreciation & Amortization | 1.41M | 3.69M | 6.55M | 7.18M | 6.42M |
| EBITDA | (64.09M) | (107.21M) | (169.4M) | (164.89M) | (212.18M) |
| EBITDA Margin | -547.9% | -741.3% | -628.0% | -467.4% | -292.3% |
| Operating Income | (65.62M) | (116.65M) | (189.95M) | (209.87M) | (247.72M) |
| Operating Margin | -561.0% | -806.6% | -704.1% | -595.0% | -341.3% |
| Interest Income | 120K | 5.76M | 14M | 34.28M | 28.46M |
| Interest Expense | 2.98M | 3.34M | 3.26M | 1.73M | 206K |
| Other Income / Expenses | (2.86M) | 2.41M | 10.74M | 36.08M | 28.91M |
| Income Before Tax | (68.48M) | (114.24M) | (179.21M) | (173.8M) | (218.81M) |
| Pre-Tax Margin | -585.5% | -789.9% | -664.3% | -492.7% | -301.4% |
| Income Tax Expense | (1.66M) | (1.52M) | 1.46M | (4.77M) | 152K |
| Net Income | (66.82M) | (112.72M) | (180.66M) | (169.03M) | (218.96M) |
| Net Margin | -571.2% | -779.3% | -669.7% | -479.2% | -301.7% |
| EPS (Basic) | (2.67) | (3.80) | (5.08) | (2.91) | (3.16) |
| EPS (Diluted) | (2.67) | (3.80) | (5.08) | (2.90) | (3.16) |
| Weighted Avg Shares | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M |
| Weighted Avg Shares (Diluted) | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.